This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
- Andrzej J. Jakubowiak, Ivan Houisse, István Májer, Ágnes Benedict, Marco Campioni, Sumeet Panjabi, Sikander Ailawadhi
- Expert Review of Hematology, October 2017, Taylor & Francis
- DOI: 10.1080/17474086.2017.1391088
